
-
New rare wild orchid seen in UK for first time in 100 years
-
Rescuers say Israeli fire kills at least 27 near Gaza aid point
-
Eurozone inflation slows sharply in May
-
Moscow parties on despite Ukraine drone attacks
-
New police search begins in hunt for missing Madeleine McCann
-
Saudi readies for 'worst case scenario' in sweltering hajj
-
Portuguese police start new search in Madeleine McCann case
-
Dutch government falls as far-right leader Wilders quits coalition
-
Wilders: firebrand 'Dutch Trump' gambles for power
-
Australian woman details fungi interest before deadly meal
-
Most markets rise as traders eye possible Trump-Xi talks
-
Rescuers say Israeli fire kills at least 15 near Gaza aid point
-
Trade war cuts global economic growth outlook: OECD
-
Year after exodus, silence fills Panama island threatened by sea
-
Former finalist Kyrgios out of Wimbledon with injury
-
Time machine: How carbon dating brings the past back to life
-
Nationalist's win dashes hopes for Polish LGBTQ, abortion rights
-
Zico warns Japan players not to follow Brazilians into transfer trap
-
Alcaraz, Swiatek and Sabalenka in French Open semi-final hunt
-
Mongolia PM resigns after anti-corruption protests
-
In Cairo, the little indie cinema that could
-
South Korea on cusp, Uzbeks eye historic World Cup spot
-
Contenders eye 'big titles' as Nations League final four kicks off
-
In Canada lake, robot learns to mine without disrupting marine life
-
Asian markets rise as traders eye possible Trump-Xi talks
-
Ancient Myanmar ball game battles for survival in troubled nation
-
Coral-rich Greek archipelago hopes to gain from trawler ban
-
Pakistan to play in Sri Lanka at India-hosted Women's World Cup
-
Lebanon on bumpy road to public transport revival
-
Ohtani leads tributes as Japan's 'Mr. Pro Baseball' dies at 89
-
'The Beautiful Game' falls for AI's charms
-
Trump 'open' to meeting Ukraine, Russia leaders to push ceasefire
-
Aiming a blow at narcos, Colombia pays farmers to uproot coca
-
Five names to watch in the Premier League transfer window
-
South Korea's six months of political chaos
-
Mongolia PM loses parliament confidence vote, resigns
-
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
-
National Energy Services Reunited Corp. Reports First Quarter Financial Results
-
Snowline Gold Further Strengthens Management Team with Appointment of VP Environment & Permitting
-
Fintech Forward Set to Return to Bahrain and Gather the Most Influential Leaders in Finance at its Third Edition in October 2025
-
WEI Named to CRN Solution Provider 500 List for 2025
-
Hemogenyx Pharmaceuticals PLC - Second Patient Passes Initial Safety Tests
-
Helium One Global Ltd - State-9 Well Drilled to TD and Free Gas Confirmed
-
Star Copper Summer Exploration Program Underway
-
Trump says Iran deal would not allow 'any' uranium enrichment
-
Stocks mixed, oil up on rising trade tensions, geopolitical risks
-
West Brom hire Spurs assistant Mason as manager
-
Oilers try to end Canada's NHL title drought by dethroning Panthers
-
Sinner crushes Rublev to reach Roland Garros last eight
-
Brazil's Bolsonaro to take the stand in coup trial

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies.
"We are pleased to be working with PeriNess, and to have the opportunity to leverage their experience for the development of Xenetic's intravenous DNase I candidate through preclinical and early-stage clinical programs. We are excited to take this step forward on the path to the clinic and look forward to investigating our systemic DNase I candidate, XBIO-015, as an adjunctive treatment," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
"We are thrilled to enter this strategic Clinical Trial Services Agreement with Xenetic and further advance the development of their systemic DNase I platform. We believe this collaboration is a great example of where we can put substantial synergies from our projects toward accelerating the clinical development of a highly promising DNase I program for patients in need of new therapies," commented Michal Ben Attar, Chief Executive Officer of PeriNess.
A large body of published preclinical data highlights the pivotal role of Neutrophil Extracellular Traps (NETs) in modulating cancer chemotherapy and immunotherapy efficacy and provides a strong rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients with pancreatic and colorectal cancers receiving chemotherapy and immunotherapy.
Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
About PeriNess Ltd.
PeriNess, a pioneering privately held Israeli company, is at the forefront of developing innovative solutions for male infertility. The company is developing a novel drug based on DNase I, which has shown potential to improve sperm quality and increase the chances of conception. PeriNess preclinical studies have shown that Neutrophil Extracellular Traps (NETs) in the blood is the deleterious factor triggering sperm damage and have confirmed that DNase treatment reduces levels of NETs in the blood, prevents sperm cell damage and improves sperm quality. With the recent completion of its Phase 1 clinical trial in Israel, PeriNess is now advancing DNase I to Phase 2 clinical trials, aiming to bring a groundbreaking new treatment to millions of couples struggling with infertility.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase I platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma , colorectal cancer and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding: the Agreement with PeriNess, including that such collaboration will bolster efforts towards clinical proof-of-concept studies in multiple indications and advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies, statements regarding the role of PeriNess under the Agreement, statements regarding the opportunity to leverage PeriNess's experience for the development of intravenous DNase I candidate through preclinical and early-stage clinical programs, and statements regarding our excitement to take this step forward on the path to the clinic and investigating our systemic DNase I candidate, XBIO-015, as an adjunctive treatment, as well as all statements regarding expectations for our DNase-base oncology platform, including our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Agreement with PeriNess; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase, XCART or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
G.Stevens--AMWN